Exhibit 99.2

WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C.

AND FERTILITY LABS OF WISCONSIN, LLC

UNAUDITED COMBINED FINANCIAL STATEMENTS

As of September 30, 2022 and for the nine months ended September 30, 2022 and 2021.

TABLE OF CONTENTS

	Page
COMBINED FINANCIAL STATEMENTS
Combined Balance Sheets	3
Combined Statements of Operations	4
Combined Statements of Member’s Capital (Deficit)	5
Combined Statements of Cash Flows	6
Notes to Combined Financial Statements	7

2

WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C.

AND FERTILITY LABS OF WISCONSIN, LLC

COMBINED BALANCE SHEETS

	September 30,			December 31,
	2022			2021
	(unaudited)
ASSETS
Current assets
Cash	$	621,220		$	627,949
Accounts receivable		275,036			136,588
Prepaid expenses and other current assets		526			-
Total current assets		896,782			764,537
Property and equipment, net		56,764			66,261
Lease right of use		1,021,588			-
Total assets	$	1,975,134		$	830,798
LIABILITIES AND MEMBERS’ DEFECIT
Current liabilities
Accounts payable	$	19,850		$	22,926
Accrued liabilities		34,185			75,605
Distributions payable		467,702			426,734
Deferred revenue		497,922			394,066
Lease liability, current portion		196,200			-
Total current liabilities		1,215,859			919,331
Lease liability, net of current portion		834,746			-
Total liabilities		2,050,605			919,331
Members’ capital (deficit)
Members’ capital (deficit)- beginning		(88,533	)		(429,537	)
Members’ capital (deficit)- current year		13,062			341,004
Total members’ capital (deficit)		(75,471	)		(88,533	)
Total liabilities and members’ capital (deficit)	$	1,975,134		$	830,798

The accompanying notes are an integral part of these combined financial statements.

3

WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C.

AND FERTILITY LABS OF WISCONSIN, LLC

UNAUDITED COMBINED STATEMENTS OF OPERATIONS

	For the Nine Months
	Ended September 30,
	2022			2021
Revenue	$	3,971,254		$	4,169,486
Cost of revenue		1,697,111			1,697,280
Gross profit		2,274,143			2,472,206
Operating expenses		953,189			886,110
Income from operations		1,320,954			1,586,096
Other income (expense):
Other income		119			182,635
Interest expense		(248	)		(124	)
Total other income (expense)		(129	)		182,511
Net income	$	1,320,825		$	1,768,607

The accompanying notes are an integral part of these combined financial statements.

4

WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C.

AND FERTILITY LABS OF WISCONSIN, LLC

UNAUDITED COMBINED STATEMENTS OF MEMBERS’ DEFICIT

Balance at January 1, 2021	$	(429,537	)
Member capital distribution		(1,538,983	)
Net income – nine months ended September 30, 2021		1,768,607
Balance at September 30, 2021		(199,913	)
Balance at January 1, 2022	$	(88,533	)
Member capital distribution		(1,307,763	)
Net income – nine months ended September 30, 2022		1,320,825
Balance at September 30, 2022	$	(75,471	)

The accompanying notes are an integral part of these combined financial statements.

5

WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C.

AND FERTILITY LABS OF WISCONSIN, LLC

UNAUDITED COMBINED STATEMENTS OF CASH FLOWS

	For the Nine Months Ended
	September 30,
	2022			2021
Cash flows from operating activities:
Net income	$	1,320,825		$	1,768,607
Adjustments to reconcile net loss to net cash used in operating activities:
Extinguishment of debt		-			(181,600	)
Depreciation and amortization		9,497			3,468
Changes in assets and liabilities:
Accounts receivable		(138,448	)		(109,329	)
Prepaid expenses and other current assets		(526	)		(60,658	)
Accounts payable		(3,076	)		3,641
Accrued liabilities		(41,420	)		(35,347	)
Deferred revenue		103,856			148,346
Leasehold liability		9,358			-
Net cash used in operating activities		1,260,066			1,537,128
Cash from investing activities:
Payments to acquire property, plant, and equipment		-			(63,389	)
Net cash used in investing activities		-			(63,389	)
Cash from financing activities:
Member capital distribution		(1,266,795	)		(1,330,343	)
Net cash provided by financing activities		(1,266,795	)		(1,330,343	)
Increase (decrease) in cash		(6,729	)		143,396
Cash at beginning of period		627,949			462,093
Cash at end of period	$	621,220		$	605,489
Supplemental disclosure of cash flow information:
Cash paid during the period for:
Interest	$	248		$	124
Supplemental disclosure of non-cash transactions:
Recognition of right of use asset and lease liability	$	1,185,824			-

The accompanying notes are an integral part of these combined financial statements.

6

WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C.

AND FERTILITY LABS OF WISCONSIN, LLC

NOTES TO THE UNAUDITED COMBINED FINANCIAL STATEMENTS

Note 1 – Summary of Significant Accounting Policies

Description of Business

The unaudited combined financial statements for Wisconsin Fertility Institute include the following business operations: Wisconsin Fertility and Reproductive Surgery Associates, S.C. (“WFRSA”), a clinic that provides fertility services and advanced gynecology care and Fertility Labs of Wisconsin, LLC (“FLOW”), a limited liability company that provides lab services exclusively to WFRSA (the “Companies”).

Basis of Presentation

The Companies’ accounting and financial reporting policies conform to accounting principles generally accepted in the United States (“U.S. GAAP”).

Use of Estimates

In preparing financial statements in conformity with U.S GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reported period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include among others: useful life of property and equipment, collectability of accounts receivable and accrued liabilities.

Cash and Cash Equivalents

For financial statement presentation purposes, the Companies consider time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. The Companies had no cash equivalents at September 30, 2022.

Accounts Receivables and Allowances for Doubtful Accounts

The allowance for doubtful accounts is based on the Companies’ assessment of the collectability of customer accounts and the aging of the related invoices and represents the Companies’ best estimate of probable credit losses in its existing trade accounts receivable. The Companies regularly review the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The allowance for doubtful accounts is included in accounts receivables, net on the Companies’ balance sheet. The Companies’ allowance for doubtful accounts balance was $33,372 and $24,071 as of September 30, 2022 and September 30, 2021 respectively.

7

Property and Equipment

The Companies record property and equipment at cost. Property and equipment is depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 to 10 years. The Companies capitalize the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Companies review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Companies had no assets or liabilities which were measured at fair value on a nonrecurring basis during the reporting periods.

Income Taxes

The Companies are limited liability companies and do not incur federal taxes. For tax purposes, the earnings and losses of the Companies are included in the members’ personal income tax returns and are taxed based on their personal tax strategies. Therefore, there is no provision or liability for federal income taxes reflected in the accompanying financial statements.

Concentration of Credit Risk

Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. The Companies did not have cash balances in excess of FDIC limits at September 30, 2022.

8

Revenue Recognition

The Companies recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach:

1.	Identify the contract with the customer.
2.	Identify the performance obligations in the contract.
3.	Determine the total transaction price.
4.	Allocate the total transaction price to each performance obligation in the contract.
5.	Recognize as revenue when (or as) each performance obligation is satisfied.

Revenue generated from clinical and lab services is recognized at the time the service is performed. The Companies’ performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue.

A portion of the Companies’ service revenue is reimbursed by third party insurance payors. Payments for services rendered to the Companies’ patients are generally less than billed charges. The Companies monitor revenue and receivables from these sources and record an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.

Patient service revenue is presented net of an estimated provision for contractual adjustments and write offs. adjustments result from the difference between the physician rates for services performed and the reimbursements by third-party insurance payors for such services. Collection of patient service revenue the Companies expect to receive is normally a function of providing complete and correct billing information to third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing. Third-party insurance payors account for approximately 15% of the Companies’ revenue.

For patient fees that are not covered by third party insurance payors, the Companies require patients to pay for services prior to the services being rendered. The Companies record these prepayments as deferred revenue until the services are rendered. Once services are rendered the Companies recognize the revenue in accordance with ASC 606.

As of September 30, 2022 and December 31, 2021 the Companies had $497,922 and $394,066 of deferred revenue, respectively.

Advertising Expense

The Companies expense advertising costs as incurred. These costs are included in the operating costs for the Companies on the statement of operations. For the nine months ended September 30, 2022 and 2021 the Companies incurred in advertising costs $7,325 and $7,991 respectively.

Recently Adopted Accounting Pronouncements

Leases (Topic 842). In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For private companies the new standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available.

The Companies adopted the standard effective January 1, 2022. The standard allows a number of optional practical expedients to use for transition. The Companies chose the certain practical expedients allowed under the transition guidance which permitted us to not to reassess any existing or expired contracts to determine if they contain embedded leases, to not to reassess our lease classification on existing leases, to account for lease and non-lease components as a single lease component for equipment leases, and whether initial direct costs previously capitalized would qualify for capitalization under FASB ASC 842. The new standard also provides practical expedients and recognition exemptions for an entity’s ongoing accounting policy elections. The Companies have elected the short-term lease recognition for all leases that qualify, which means that we do not recognize a ROU asset and lease liability for any lease with a term of twelve months or less. See Note 3 for more details.

The most significant impact of adopting the standard was the recognition of ROU assets and lease liabilities for operating leases on the Companies’ consolidated balance sheet but it did not have an impact on the Companies’ consolidated statements of operations or consolidated statements of cash flows. The Companies did not have a cumulative effect on adoption prior to January 1, 2022.

9

Note 2 – Property and Equipment

Property and equipment consists of the following:

	September 30, 2022			December 31, 2021
Furniture and equipment	$	10,784		$	10,784
Leasehold improvements		63,390			63,389
Less: accumulated depreciation		(17,410	)		(7,912	)
Total equipment, net	$	56,764		$	66,261

During the nine months ended September 30, 2022, and 2021, the Companies recorded depreciation expense of $9,497 and $3,468.

Note 3 – Leases

The Companies have an operating lease agreement in place for its office. Per FASB’s ASU 2016-02, Leases Topic 842 (“ASU 2016-02”), effective January 1, 2022, the Companies are required to report a right-of-use asset and corresponding liability to report the present value of the total lease payments, with appropriate interest calculation. Per the terms of ASU 2016-02, the Companies can use its implicit interest rate, if known, or applicable federal rate otherwise. Since the Companies’ implicit interest rate was not readily determinable, the Companies utilized the applicable federal rate, as of the commencement of the lease. Lease renewal options included in any lease are considered in the lease term if it is reasonably certain the Companies will exercise the option to renew. The Companies’ operating lease agreements do not contain any material restrictive covenants.

As of September 30, 2022, the Companies’ lease components included in the combined balance sheet were as follows:

Lease component	Balance sheet classification	September 30, 2022
Assets
ROU assets – operating lease	Other assets	$	1,021,588
Total ROU assets		$	1,021,588
Liabilities
Current operating lease liability	Current liabilities	$	196,200
Long-term operating lease liability	Other liabilities		834,746
Total lease liabilities		$	1,030,946

Future minimum lease payments as of September 30, 2022 were as follows:

2022	$	55,903
2023		227,804
2024		233,499
2025		239,337
2026 and beyond		307,026
Total future minimum lease payments	$	1,063,569
Less: Interest		(32,623	)
Total operating lease liabilities	$	1,030,946

10

Note 4 – Notes Payable

Paycheck Protection Program

On April 15, 2020, the Companies received a loan in the principal amount of $181,600 pursuant to the U.S. Small Business Administration’s Paycheck Protection Program. The loan matured 18 months from the date of funding, was payable over 18 equal monthly installments, and had an interest of 1% per annum. Up to 100% of the principal balance of the loan was forgivable based upon satisfaction of certain criteria under the Paycheck Protection Program. On February 24, 2021, the principal of the loan as well as $1,567 of accrued interest was forgiven and the note was extinguished. The Companies recognized a gain of $181,600 on extinguishment of debt during the nine months ended September 30, 2021.

Note 5 – Members’ Distributions

Members’ distributions totaling $1,266,795 and $1,330,343 were paid out during the nine months ended September 30, 2022 and 2021, respectively. Distributions payable to the members totaled $467,702 and $572,608 at September 30, 2022 and 2021, respectively.

Note 6 – Commitments and Contingencies

Insurance

The Companies’ insurance coverage is carried with third-party insurers and includes: (i) general liability insurance covering third-party exposures; (ii) statutory workers’ compensation insurance; (iv) excess liability insurance above the established primary limits for general liability and automobile liability insurance; (v) property insurance, which covers the replacement value of real and personal property and includes business interruption; and (vi) malpractice insurance covering our physicians for acts related to our business activities. All coverage is subject to certain limits and deductibles, the terms and conditions of which are common for companies with similar types of operations.

Legal Matters

The Companies are not currently subject to any material legal proceedings; however, it could be subject to legal proceedings and claims from time to time in the ordinary course of its business, or legal proceedings it considered immaterial may in the future become material. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve, and can divert management resources.

Note 7 – Subsequent Events

On March 16, 2023, INVO Bioscience Inc., a Nevada corporation (“INVO”), through Wood Violet Fertility LLC, a Delaware limited liability company (“Buyer”) and wholly-owned subsidiary of INVO Centers LLC, a Delaware company wholly-owned by INVO, entered into an Asset Purchase Agreement (the “APA”) with WFRSA and The Elizabeth Pritts Revocable Living Trust (the “Seller,” together with WFRSA, the “Seller Parties”) pursuant to which Buyer agreed to acquire the Purchased Assets (as defined in the APA) related to WFRSA’s business. Buyer also agreed to assume certain liabilities of WFRSA as set forth in the APA. Certain non-clinical assets, properties and rights of WFRSA shall be excluded from the Purchased Assets including patient lists, charts, records and ledgers, all contracts with Payors (as defined in the APA); all Health Care Permits (as defined in the APA).

The Buyer will deliver to WFRSA an amount equal to (all capitalized terms as defined in the APA) the Closing Payment at closing consisting of $500,000 less Target Closing Date Debt less the Holdback Amount of $280,000. Buyer has agreed to make the following Post-Closing Additional Payments of $500,000 on each of the first three anniversaries of closing provided that Seller may elect to receive shares of INVO common stock in lieu of such cash payments as follows: (i) 80,000 shares of INVO common stock on the first additional payment date; (ii) 55,000 shares of INVO common stock on the second additional payment date and (iii) 35,000 shares of INVO common stock on the third additional payment date. The Additional Payments are secured by Seller having a subordinated lien on the Purchased Assets.

On March 16, 2023, Buyer entered into a Membership Interest Purchase Agreement (the “MIPA”) with FLOW, IVF Science, LLC, a Wisconsin limited liability company owned by Wael Megid, Ph.D., and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust, a Trust created under the laws of the State of Wisconsin (each, a “Selling Member” and collectively, the “Selling Members”). Under the MIPA the Selling Members agreed to sell to Buyer 100% of the Membership Interests of FLOW for a purchase price equal to (all capitalized terms as defined in the MIPA) the Initial Purchase Price, which is equal to (i) two million dollars ($2,000,000) minus (ii) the Closing Indebtedness minus (iii) any Transaction Expenses minus (iv) the Holdback Amount of $70,000. In addition to the Initial Closing Payment, Purchaser has agreed to pay to the Selling Members additional payments of $2,000,000 within 90-days of each of the first three anniversaries of closing provided that Selling Members may elect to receive shares of INVO common stock in lieu of such cash payments as follows: (i) 320,000 shares of INVO common stock on the first additional payment date; (ii) 220,000 shares of INVO common stock on the second additional payment date and (iii) 140,000 shares of INVO common stock on the third additional payment date. These additional payments are secured by the Selling Members having a lien on the assets of FLOW.

11